Invokana (Janssen Pharmaceuticals) shows greater benefit than conventional therapy for Type 2 Diabetes

Results from a new 52-week Phase III clinical study, showing 300 milligrams (mg) of Invokana (canagliflozin), from Janssen Pharmaceuticals, provided greater improvements in blood glucose control compared to a commonly prescribed therapy, sitagliptin, in adult patients with Type 2 Diabetes taking background metformin. The study also showed that Invokana (100 mg) provided similar improvements in blood glucose control to sitagliptin, and both doses of Invokana resulted in greater secondary endpoint reductions in body weight and blood pressure.

Results of a second Phase III study, also in adult patients taking metformin, showed greater improvements in blood glucose control with Invokana (300mg) and similar improvements with Invokana (100mg) compared to glimepiride over a period of 104 weeks. Both doses of Invokana provided greater secondary endpoint reductions in body weight and blood pressure than glimepiride. Data were presented at the American Diabetes Association Scientific Sessions.